[{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"9-delta-Tetrahydrocannabinol-valine-hemisuccinate","moa":"CB receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Skye Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Skye Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Santen","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Santen"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Alcon Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alcon Inc \/ Not Applicable"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon Inc"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Netarsudil","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alcon Inc","amount2":0.93000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.93000000000000005,"dosageForm":"Solution\/Drops","sponsorNew":"Alcon Inc \/ Alcon Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alcon Inc \/ Alcon Inc"}]

Find Clinical Drug Pipeline Developments & Deals for Netarsudil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

                          Brand Name : Rocklatan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 22, 2022

                          Lead Product(s) : Netarsudil,Latanoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alcon Inc

                          Deal Size : $930.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye di...

                          Brand Name : Rocklatan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 22, 2022

                          Lead Product(s) : Netarsudil,Latanoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alcon Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmace...

                          Brand Name : Rocklatan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 22, 2022

                          Lead Product(s) : Netarsudil,Latanoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Alcon Inc

                          Deal Size : $930.0 million

                          Deal Type : Acquisition

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B cl...

                          Brand Name : Rocklatan

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 20, 2022

                          Lead Product(s) : Netarsudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...

                          Brand Name : Rhopressa

                          Molecule Type : Small molecule

                          Upfront Cash : $88.0 million

                          December 07, 2021

                          Lead Product(s) : Netarsudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Santen Pharmaceutical

                          Deal Size : $168.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Lead Product(s) : 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

                          Therapeutic Area : Ophthalmology

                          Study Phase : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.

                          Brand Name : THC-VHS

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 21, 2021

                          Lead Product(s) : 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.

                          Brand Name : Rhopressa

                          Molecule Type : Small molecule

                          Upfront Cash : $50.0 million

                          October 28, 2020

                          Lead Product(s) : Netarsudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Santen Pharmaceutical

                          Deal Size : $149.0 million

                          Deal Type : Licensing Agreement

                          blank